Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsekimig versus placebo in high-risk adults with asthma not currently suitable for biologic treatment
CTR20244663Phase 2Active
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lunsekimig in asthma, sponsored by Sanofi. Started Apr 2025; status: active.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20244663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244663.